Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

ClinicalTrials.gov ID: NCT04099251

Public ClinicalTrials.gov record NCT04099251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma

Study identification

NCT ID
NCT04099251
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
790 participants

Conditions and interventions

Conditions

Interventions

  • Nivolumab Biological
  • Placebo Other

Biological · Other

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 27, 2019
Primary completion
Jun 27, 2022
Completion
Nov 29, 2026
Last update posted
Jun 22, 2026

2019 – 2026

United States locations

U.S. sites
32
U.S. states
21
U.S. cities
27
Facility City State ZIP Site status
Local Institution - 0088 Birmingham Alabama 35294-3300
Local Institution - 0126 Tucson Arizona 85724-5024
Local Institution - 0087 Springdale Arkansas 72762
Local Institution - 0080 Los Angeles California 90025
Local Institution - 0077 San Francisco California 94115
Local Institution - 0119 San Francisco California 94115
Local Institution - 0122 San Jose California 95119
Local Institution - 0121 Vallejo California 94589-2441
Local Institution - 0109 Vallejo California 94589
Local Institution - 0120 Vallejo California 94589
Local Institution - 0091 Aurora Colorado 80045
Local Institution - 0089 Washington D.C. District of Columbia 20057
Local Institution - 0141 Atlanta Georgia 30342
Local Institution - 0132 Chicago Illinois 60611
Local Institution - 0135 Baltimore Maryland 21237
Local Institution - 0078 Boston Massachusetts 02215
Local Institution - 0127 Boston Massachusetts 02215
Local Institution - 0143 Boston Massachusetts 02215
Local Institution - 0151 Minneapolis Minnesota 55407
Local Institution - 0081 Robbinsdale Minnesota 55407
Local Institution - 0079 Omaha Nebraska 68130
Local Institution - 0093 Hackensack New Jersey 07601
Local Institution - 0094 New York New York 10016
Local Institution - 0086 Charlotte North Carolina 28204
Local Institution - 0099 Cleveland Ohio 44195
Local Institution - 0076 Portland Oregon 97213
Local Institution - 0092 Allentown Pennsylvania 18103
Local Institution - 0031 Pittsburgh Pennsylvania 15232
Local Institution - 0148 Germantown Tennessee 38138
Local Institution - 0144 Austin Texas 78731
Local Institution - 0085 Dallas Texas 75246
Local Institution - 0090 Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04099251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2026 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04099251 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →